A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma
Latest Information Update: 16 Jul 2024
At a glance
- Drugs Carmustine (Primary) ; Cytarabine (Primary) ; Etoposide (Primary) ; Melphalan (Primary) ; Romidepsin (Primary)
- Indications Adult T-cell leukaemia-lymphoma; Anaplastic large cell lymphoma; Cutaneous T-cell lymphoma; Extranodal NK-T-cell lymphoma; Mycosis fungoides; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Sezary syndrome; T-cell lymphoma
- Focus Therapeutic Use
- 03 Jul 2024 Planned End Date changed from 1 Jul 2024 to 1 Jul 2025.
- 03 Jul 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Jul 2025.
- 29 Jun 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.